Rescue of Murine F508del CFTR Activity in Native Intestine by Low Temperature and Proteasome Inhibitors

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wilke, Martina ^a   Bot, Alice ^a   Jorna, Huub ^a   Scholte, Bob J ^a   de Jonge, Hugo R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BREFELDIN A; CHLORIDE ION; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPOXOMICIN; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHLORIDE TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EX VIVO STUDY; GENE; GENE DELETION; INCUBATION TIME; INTESTINAL SECRETION; INTESTINE CELL; INTESTINE CRYPT; INTESTINE EPITHELIUM; LOW TEMPERATURE; LOW TEMPERATURE PROCEDURES; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; CHLORIDES; COLD TEMPERATURE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; INTESTINAL MUCOSA; INTESTINES; MICE; MICE, KNOCKOUT; MUTATION; PROTEASOME INHIBITORS;

MURINAE;

EID: 84871352589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052070     Document Type: Article

References (70)

1. Kartner N, Augustinas O, Jensen TJ, Naismith AL, Riordan JR, (1992) Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1: 321-327.
2. Trezise AE, Buchwald M, (1991) In vivo cell-specific expression of the cystic fibrosis transmembrane conductance regulator. Nature 353: 434-437.
3. van Doorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, et al. (1995) A mouse model for the cystic fibrosis delta F508 mutation. Embo J 14: 4403-4411.
4. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM, (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 19: 575-606.
5. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, et al. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834.
6. French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, et al. (1996) A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest 98: 1304-1312.
7. Turnbull EL, Rosser MF, Cyr DM, (2007) The role of the UPS in cystic fibrosis. BMC Biochem 8 Suppl 1: S11.
8. Riordan JR, (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726.
9. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE, (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78: 959-991.
10. Coppinger JA, Hutt DM, Razvi A, Koulov AV, Pankow S, et al. (2012) A chaperone trap contributes to the onset of cystic fibrosis. PLoS One 7: e37682.
11. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, et al. (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354: 526-528.
12. Drumm ML, Wilkinson DJ, Smit LS, Worrell RT, Strong TV, et al. (1991) Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 254: 1797-1799.
13. Varga K, Goldstein RF, Jurkuvenaite A, Chen L, Matalon S, et al. (2008) Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 410: 555-564.
14. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, et al. (2010) Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329: 805-810.
15. Verkman AS, Galietta LJ, (2009) Chloride channels as drug targets. Nat Rev Drug Discov 8: 153-171.
16. Wang Y, Bartlett MC, Loo TW, Clarke DM, (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70: 297-302.
17. Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, et al. (2009) A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 75: 1430-1438.
18. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, et al. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764.
19. Rennolds J, Boyaka PN, Bellis SL, Cormet-Boyaka E, (2008) Low temperature induces the delivery of mature and immature CFTR to the plasma membrane. Biochem Biophys Res Commun 366: 1025-1029.
20. Cormet-Boyaka E, Hong JS, Berdiev BK, Fortenberry JA, Rennolds J, et al. (2009) A truncated CFTR protein rescues endogenous {Delta}F508-CFTR and corrects chloride transport in mice. Faseb J.
21. Owsianik G, Cao L, Nilius B, (2003) Rescue of functional DeltaF508-CFTR channels by co-expression with truncated CFTR constructs in COS-1 cells. FEBS Lett 554: 173-178.
22. Sato S, Ward CL, Kopito RR, (1998) Cotranslational ubiquitination of cystic fibrosis transmembrane conductance regulator in vitro. J Biol Chem 273: 7189-7192.
23. Fischer H, Fukuda N, Barbry P, Illek B, Sartori C, et al. (2001) Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 281: L52-57.
24. Rubenstein RC, Zeitlin PL, (2000) Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 278: C259-267.
25. Becq F, Mettey Y, Gray MA, Galietta LJ, Dormer RL, et al. (1999) Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem 274: 27415-27425.
26. DeCarvalho AC, Gansheroff LJ, Teem JL, (2002) Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. J Biol Chem 277: 35896-35905.
27. Aleksandrov AA, Kota P, Aleksandrov LA, He L, Jensen T, et al. (2010) Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. J Mol Biol 401: 194-210.
28. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, et al. (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564-2571.
29. Pedemonte N, Tomati V, Sondo E, Galietta LJ, (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298: C866-874.
30. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, et al. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117-1130.
31. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106: 18825-18830.
32. Carlile GW, Robert R, Zhang D, Teske KA, Luo Y, et al. (2007) Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 8: 1012-1020.
33. Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, et al. (2010) Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 24: 971-991.
34. Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, et al. (2010) DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23: 268-278.
35. Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN, et al. (2011) Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 10 Suppl 2: S152-171.
36. Norez C, Noel S, Wilke M, Bijvelds M, Jorna H, et al. (2006) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 580: 2081-2086.
37. Robert R, Carlile GC, Liao J, Balghi H, Lesimple P, et al. (2010) Correction of {Delta}F508-CFTR trafficking defect by the bioavailable compound glafenine. Mol Pharmacol.
38. Ward CL, Omura S, Kopito RR, (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83: 121-127.
39. Vij N, Fang S, Zeitlin PL, (2006) Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 281: 17369-17378.
40. Belcher CN, Vij N, (2010) Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies. Curr Mol Med 10: 82-94.
41. French PJ, Bijman J, Bot AG, Boomaars WE, Scholte BJ, et al. (1997) Genistein activates CFTR Cl- channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am J Physiol 273: C747-753.
42. DeJonge H, Ballmann M, Bronsveld I, Sinaasappel M, Stanke F, et al. (2004) Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cystic Fibrosis 3In press.
43. van Dommelen FS, Hamer CM, De Jonge HR, (1986) Efficient entrapment of large and small compounds during vesiculation of intestinal microvilli. Biochem J 236: 771-778.
44. Xiao F, Li J, Singh AK, Riederer B, Wang J, et al. (2012) Cystic fibrosis transmembrane conductance regulator mutant F508del membrane expression rescues epithelial HCO3- secretion in murine intestine. J Physiol.
45. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, et al. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83: 129-135.
46. Gentzsch M, Chang XB, Cui L, Wu Y, Ozols VV, et al. (2004) Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 15: 2684-2696.
47. Gee HY, Noh SH, Tang BL, Kim KH, Lee MG, (2011) Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway. Cell 146: 746-760.
48. Du K, Sharma M, Lukacs GL, (2005) The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12: 17-25.
49. Bjerknes M, Cheng H, (2006) Intestinal epithelial stem cells and progenitors. Methods Enzymol 419: 337-383.
50. Gelman MS, Kannegaard ES, Kopito RR, (2002) A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator. J Biol Chem 277: 11709-11714.
51. Rabeh WM, Bossard F, Xu H, Okiyoneda T, Bagdany M, et al. (2012) Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell 148: 150-163.
52. Mendoza JL, Schmidt A, Li Q, Nuvaga E, Barrett T, et al. (2012) Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 148: 164-174.
53. Fisher JT, Liu X, Yan Z, Luo M, Zhang Y, et al. (2012) Comparative processing and function of human and ferret cystic fibrosis transmembrane conductance regulator. J Biol Chem 287: 21673-21685.
54. Cholon DM, O'Neal WK, Randell SH, Riordan JR, Gentzsch M, (2010) Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol 298: L304-314.
55. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, et al. (2010) Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol.
56. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, et al. (2012) Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DeltaF508 cystic fibrosis transmembrane conductance regulator. Autophagy 8.
57. Vij N, Min T, Marasigan R, Belcher CN, Mazur S, et al. (2010) Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnology 8: 22.
58. Vij N, Mazur S, Zeitlin PL, (2009) CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One 4: e4664.
59. Bodas M, Vij N, (2010) The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 9: 346-356.
60. Kisselev AF, Goldberg AL, (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758.
61. Richardson PG, Mitsiades C, Hideshima T, Anderson KC, (2005) Proteasome inhibition in the treatment of cancer. Cell Cycle 4: 290-296.
62. Orlowski RZ, Kuhn DJ, (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657.
63. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420-4427.
64. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617.
65. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, et al. (2004) Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22: 115-119.
66. Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, et al. (2011) Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 17: 7313-7323.
67. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, et al. (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17: 5311-5321.
68. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP, (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11: 239-253.
69. Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge HR, et al. (2001) Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 108: 1705-1715.
70. Bronsveld I, Mekus F, Bijman J, Ballmann M, Greipel J, et al. (2000) Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology 119: 32-40.